Evidence map›Paper›PMID 31269329›Full record

ArticleCancer medicine2019

PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories.

Ana-Iris Schiefer, Elisabeth Salzer, Anna Füreder, Zsolt Szepfalusi, Thomas Müller-Sacherer, Wolf-Dietrich Huber, Ina Michel-Behnke, Anita Lawitschka, Herbert Pichler, Georg Mann and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Ana-Iris SchieferDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Elisabeth SalzerDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
Anna FürederDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
Zsolt SzepfalusiDepartment of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Thomas Müller-SachererDepartment of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Wolf-Dietrich HuberDepartment of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Ina Michel-BehnkeDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Cardiology, Pediatric Heart Center, Medical University of Vienna, Vienna, Austria.
Anita LawitschkaDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
Herbert PichlerDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
Georg MannDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
Caroline HutterDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
Ingrid Simonitsch-KluppDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Andishe AttarbaschiDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.ORCID 0000-0002-9285-6898
Medical University of Vienna · ATSt Anna Children's Hospital · ATAustrian Academy of Sciences · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy of children with post-transplantation lymphoproliferative disorder (PTLD) after hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) can be challenging. In this retrospective study, we investigated PD-L1 and PD1 expression in all PTLD categories of childhood and adolescence to see whether checkpoint inhibition with PD-L1/PD1 inhibitors may serve as a therapy option. We included 21 patients aged 19 years or younger (at date of transplant) with PTLD following SOT or HSCT having adequate tumor samples available (n = 29). Using immunohistochemistry, we evaluated PD-L1/PD1 expression on both tumor cells and cells of the microenvironment in all samples. Availability of consecutively matched tumor samples during 6 of 21 patients' disease courses also allowed an intra-individual assessment of PD-L1/PD1 expression. We observed lower PD-L1 and higher PD1 expression in non-destructive lesions, and higher PD-L1 and lower PD1 expression in polymorphic and, in particular, in monomorphic PTLD, mostly diffuse large B-cell lymphomas (DLBCL, n = 10/21). The amount of PD-L1- and PD1-positive cells changed in the opposite way in sequential biopsies of the same individual correlating well with the PTLD category. This is the first comprehensive pediatric study assessing PD-L1 and PD1 expression on tumor cells and in the microenvironment of PTLD including not only monomorphic, but also non-destructive early lesions. PD-L1 expression of the tumor cells inversely correlated with PD1 expression in surrounding tissues, with the highest expression in DLBCL. Since PTLD can be therapeutically challenging, our results indicate a potential efficacy of checkpoint inhibitors if standard immune- and/or chemotherapy fail or are impossible. We therefore recommend routine staining of PD-L1 and PD1 in all PTLD categories.

Indexed as

AdolescentB7-H1 AntigenChildChild, PreschoolFemaleGene Expression Regulation, NeoplasticGenetic HeterogeneityHematopoietic Stem Cell TransplantationHumansInfantLymphoproliferative DisordersMaleProgrammed Cell Death 1 ReceptorRetrospective StudiesTumor MicroenvironmentYoung AdultB7-H1 AntigenCD274 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorexpressionPD1PD-L1post-transplantation lymphoproliferative disease (PTLD)PTLD category

Identifiers

PMID31269329
PMCPMC6712474
OpenAlexW2954406253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.